Edition:
United Kingdom

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

10.10USD
17 Jul 2018
Change (% chg)

-- (--)
Prev Close
$10.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
23,501
52-wk High
$11.00
52-wk Low
$2.15

Chart for

About

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment... (more)

Overall

Beta: 0.69
Market Cap(Mil.): $178.35
Shares Outstanding(Mil.): 17.66
Dividend: --
Yield (%): --

Financials

  XENE.OQ Industry Sector
P/E (TTM): -- 214.90 33.15
EPS (TTM): -1.50 -- --
ROI: -59.10 -3.85 13.23
ROE: -84.26 -5.38 15.27

BRIEF-Xenon Pharmaceuticals Q1 Net Loss Per Common Share $0.21

* XENON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

08 May 2018

BRIEF-Xenon Pharmaceuticals Enters Into At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co

* XENON PHARMACEUTICALS INC - ON MAY 8, CO ENTERED INTO AN AT--MARKET EQUITY OFFERING SALES AGREEMENT WITH STIFEL, NICOLAUS & COMPANY - SEC FILING

08 May 2018

BRIEF-Xenon Pharmaceuticals To Host Conference Call To Discuss Q1 2018 Financial Results

* XENON PHARMACEUTICALS TO HOST CONFERENCE CALL AND WEBCAST TO DISCUSS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

01 May 2018

BRIEF-Xenon Pharma, Teva Pharma Terminate Development & License Agreement

* XENON PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

07 Mar 2018

BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial

* XENON PHARMACEUTICALS ADVANCES SECOND PROPRIETARY EPILEPSY PRODUCT INTO THE CLINIC WITH INITIATION OF XEN901 PHASE 1 CLINICAL TRIAL Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

20 Feb 2018

Earnings vs. Estimates